Automated insulin delivery improves glycemic control of type 2 diabetes in randomized trial

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery (AID) in adults with insulin-treated type 2 diabetes. AID significantly lowered glycated hemoglobin (HbA1c) levels and improved glucose control compared to standard insulin therapy with continuous glucose monitoring (CGM).

Antibody-based therapy is several steps closer to treat lethal mucormycosis

Mucormycosis, a fungal infection caused by Mucorales, has high mortality rates in people with weakened immune systems and those suffering from severe trauma like burns, blast injuries or victims of natural disasters. The disease caused serious infection among COVID-19 patients treated with high doses of corticosteroids with mortality rates close to 60 percent. In the United States, there are approximately 4,000 cases per year with a rate of 200,000 in Southeast Asia where the disease is endemic to India. While vaccines and immunotherapies are available for viruses and bacteria, effective antifungal immunotherapies for mucormycosis, specifically, are lacking.